Literature DB >> 17509990

The diagnostic role of claudins in serous effusions.

Lilach Kleinberg1, Arild Holth, Eduard Fridman, Ignat Schwartz, Ie-Ming Shih, Ben Davidson.   

Abstract

We analyzed the diagnostic role of claudins in effusion cytology in 325 effusions, including 218 ovarian, 49 breast, 15 cervical or endometrial, 10 gastrointestinal, and 8 lung adenocarcinomas and 25 malignant mesotheliomas (MMs). Specimens were analyzed for claudin-1 and claudin-3 expression using immunohistochemical analysis. Ovarian and breast adenocarcinoma were further analyzed for claudin-7 expression. Claudin-1 expression was most frequent in ovarian and cervical or endometrial adenocarcinoma compared with other adenocarcinomas and MMs (P < .001). Claudin-3 expression was comparable in adenocarcinomas of different origin but was absent in MMs (P < .001). Reactive mesothelial cells rarely expressed claudins. Claudin-7 expression was higher in ovarian than in breast adenocarcinoma (P < .001). Our data suggest that expression of claudin-3 or claudin-7 is specific for adenocarcinoma and rules out the diagnosis of cells as mesothelial and that absence of claudin-1 expression excludes ovarian carcinoma as the possible origin of metastatic adenocarcinoma. Claudins may, therefore, be of diagnostic value in effusion cytology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509990     DOI: 10.1309/V025QRN3R9CJGNPX

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  15 in total

1.  Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers.

Authors:  Heta Merikallio; Paavo Pääkkö; Terttu Harju; Ylermi Soini
Journal:  Int J Clin Exp Pathol       Date:  2011-09-27

2.  PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.

Authors:  Y Yuan; H P Dong; D A Nymoen; J M Nesland; C Wu; B Davidson
Journal:  Cytopathology       Date:  2011-02       Impact factor: 2.073

3.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

4.  The diagnostic role of PTEN and ARID1A in serous effusions.

Authors:  Ben Davidson; Maurizio Pinamonti; Dolors Cuevas; Arild Holth; Pio Zeppa; Thomas Hager; Jeremias Wohlschlaeger; Martin Tötsch
Journal:  Virchows Arch       Date:  2017-11-24       Impact factor: 4.064

5.  iTRAQ-coupled 2D LC/MS-MS analysis of CXCR7-transfected papillary thyroid carcinoma cells: A new insight into CXCR7 regulation of papillary thyroid carcinoma progression and identification of potential biomarkers.

Authors:  Hengwei Zhang; Lei Yang; Zhangyi Liu; Chenxi Liu; Xuyong Teng; Lei Zhang; Bo Yin; Zhen Liu
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

6.  Tenascin-X is a novel diagnostic marker of malignant mesothelioma.

Authors:  Yuan Yuan; Dag André Nymoen; Helene Tuft Stavnes; Anne Katrine Rosnes; Ola Bjørang; Chuanyue Wu; Jahn M Nesland; Ben Davidson
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

Review 7.  Claudin and ovarian cancer.

Authors:  Chinmoy K Bose; Ashis Mukhopadhyay
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

8.  Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion.

Authors:  Neetu Dahiya; Kevin G Becker; William H Wood; Yongqing Zhang; Patrice J Morin
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

9.  Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Authors:  Mandi M Murph; Wenbin Liu; Shuangxing Yu; Yiling Lu; Hassan Hall; Bryan T Hennessy; John Lahad; Marci Schaner; Aslaug Helland; Gunnar Kristensen; Anne-Lise Børresen-Dale; Gordon B Mills
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

10.  Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer.

Authors:  M Lal-Nag; M Battis; A D Santin; P J Morin
Journal:  Oncogenesis       Date:  2012-11-12       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.